British Journal of Clinical Pharmacology

Papers
(The H4-Index of British Journal of Clinical Pharmacology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Issue Highlights87
71
Issue Information61
57
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food51
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population51
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’50
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection47
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre46
Letter to the editor of the Brit J Clin Pharmacol on Hartjes et al. 2025 https://doi.org/10.1002/bcp.7017644
A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials44
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients44
Impact of codeine rescheduling on prescribing of codeine and other opioids: Interrupted time series analyses using Australian general practice data40
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination39
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery39
Neck‐vein thrombosis during spaceflight38
Modelling the progression of illicit substance use patterns from real‐world evidence38
Lemborexant levels in breast milk after single doses in healthy, lactating women36
Selected Abstracts from Pharmacology 202436
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients33
Understanding the influence of transfusion and blood loss on tranexamic acid concentration in scoliosis surgery with blood loss33
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry32
Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II32
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia31
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing30
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial29
A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol29
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity29
Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase29
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial29
0.22371101379395